Effective next step treatment for allergic rhinitis

Dymista® - twice as effective as monotherapy

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

The combination spray containing azelastine (AZ) and fluticasone (FP), Dymista®, has been shown to be twice as effective as fluticasone propionate or azelastine alone at treating the entire rhinitis symptom spectrum:1,2

In a randomized, double-blind, placebo-controlled, 2-week trial involving 779 patients with moderate-to-severe seasonal allergic rhinitis, Dymista® (MP29-02) administered as one spray to each nostril twice-daily provided greater nasal and ocular symptom improvement than azelastine (AZ) or fluticasone propionate (FP) administered alone (one spray to each nostril twice-daily).1

  • Slide
  • Slide

In the meta-analysis Dymista® (MP29-02) reduced the mean reflective total nasal symptom score from baseline more than FP, azelastine or placebo.

This benefit was observed from the first day of assessment, With improvement in each individual nasal symptom, even in the patients with the most severe disease Dymista® (MP29-02) achieved response consistently days earlier and showed greater efficacy in patients with moderate-to-severe rhinitis than FP and azelastine 2

Experts Corner

Click below to hear what two experts have to say about the effectiveness of Dymista® on the full spectrum of allergic rhinitis symptoms

Further Your Understanding

Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.

  • Allergi
    Allergic Rhinitis
  • Impact
    Impact of Rhinitis
  • Impact
    Onset
  • Impact
    Treatment
  • Guidelines
    Guidelines
  • Clinical Papers
    Clinical Papers

References

  1. Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasonepropionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy AsthmaProc. 2012; 33: 324-332.
  2. Carr W, Bernstein J, Lieberman P, el al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin lmmonul. 2012; 129: 1282-1289.

Want to expand your knowledge on Allergic Rhinitis?

Register to MylanConnects and subscribe to our Allergy newsletters to continue reading.

Mylan Connects

Mylan Connects is an online platform for healthcare professionals. Register today and enjoy this article and a selection of others for free.

REGISTER NOW

hcp popup title

Mylan Connects is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Mylan Connects today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW